Significant Role of Magnetic Resonance Imaging for the Diagnosis and Evaluation of Cardiac Amyloidosis in Primary Light Chain Amyloidosis

Overview

Journal J Clin Exp Hematop

Specialties Hematology
Pathology

Date 2020 Aug 12

PMID 32779613

Authors

Yasunobu Sekiguchi

Mutsumi Wakabayashi

Hiroko Iizuka

Haruko Takizawa

Keiji Sugimoto

Sakura Sakajiri

Tadaaki Inano

Yasutaka Fukuda

Yasuharu Hamano

Shigeki Tomita

Hiroshi Izumi

Hiroyuki Isogai

Mitsuo Okubo

Noriko Nakamura

Tomohiro Sawada

Kimihiro Matsumoto

Masaaki Noguchi

Affiliations

Soon will be listed here.

Abstract

A 47-year-old male with macroglossia presented with dyspnea on effort and chest pain at rest. Cardiac MRI revealed diffuse global subendocardial late gadolinium enhancement below the left ventricular endocardium and a dark blood pool of intracardiac contrast medium. Tongue biopsy revealed amyloid deposition, which was limited in the myocardium. He was diagnosed with primary light chain amyloidosis. His condition was stage I according to the Mayo Clinic staging system. He underwent autologous peripheral blood stem cell transplantation. On Day 10, he developed chest pain and died suddenly on Day 11. Postmortem examination revealed amyloid deposition throughout the heart.

References

Wechalekar A, Gillmore J, Bird J, Cavenagh J, Hawkins S, Kazmi M . Guidelines on the management of AL amyloidosis. Br J Haematol. 2014; 168(2):186-206. DOI: 10.1111/bjh.13155. View

Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y . High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. Int J Hematol. 2015; 103(3):299-305. DOI: 10.1007/s12185-015-1922-x. View

Girnius S, Seldin D, Meier-Ewert H, Sloan J, Quillen K, Ruberg F . Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant. 2013; 49(3):434-9. DOI: 10.1038/bmt.2013.192. View

Wechalekar A, Hawkins P, Gillmore J . Perspectives in treatment of AL amyloidosis. Br J Haematol. 2007; 140(4):365-77. DOI: 10.1111/j.1365-2141.2007.06936.x. View

Gertz M, Lacy M, Dispenzieri A, Kumar S, Dingli D, Leung N . Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2012; 48(4):557-61. DOI: 10.1038/bmt.2012.170. View

Falk R, Comenzo R, Skinner M . The systemic amyloidoses. N Engl J Med. 1997; 337(13):898-909. DOI: 10.1056/NEJM199709253371306. View

Comenzo R, Gertz M . Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002; 99(12):4276-82. DOI: 10.1182/blood.v99.12.4276. View

Hayashi T, Ikeda H, Igarashi T, Maruyama Y, Aoki Y, Nojima M . Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP. Int J Hematol. 2014; 100(6):554-8. DOI: 10.1007/s12185-014-1680-1. View

Donnelly J, Hanna M . Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017; 84(12 Suppl 3):12-26. DOI: 10.3949/ccjm.84.s3.02. View

10.

Lin L, Li X, Feng J, Shen K, Tian Z, Sun J . The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson. 2018; 20(1):2. PMC: 5753536. DOI: 10.1186/s12968-017-0419-6. View

11.

Kumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F, Colby C . Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30(9):989-95. PMC: 3675680. DOI: 10.1200/JCO.2011.38.5724. View

12.

Gertz M, Lacy M, Dispenzieri A, Kumar S, Buadi F, Dingli D . Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2010; 46(7):970-5. DOI: 10.1038/bmt.2010.234. View

13.

Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt M, Therneau T . Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22(18):3751-7. DOI: 10.1200/JCO.2004.03.029. View

14.

Sher T, Dispenzieri A, Gertz M . Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2015; 22(5):796-801. DOI: 10.1016/j.bbmt.2015.10.010. View

15.

Skinner M, Sanchorawala V, Seldin D, Dember L, Falk R, Berk J . High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004; 140(2):85-93. DOI: 10.7326/0003-4819-140-2-200401200-00008. View

16.

Tsai S, Seldin D, Quillen K, Berk J, Ruberg F, Meier-Ewert H . High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood. 2012; 120(22):4445-6. DOI: 10.1182/blood-2012-09-457341. View

17.

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L . Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica. 2006; 91(12):1635-43. View

18.

Gertz M, Comenzo R, Falk R, Fermand J, Hazenberg B, Hawkins P . Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-28. DOI: 10.1002/ajh.20381. View

19.

Comenzo R, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H . Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012; 26(11):2317-25. DOI: 10.1038/leu.2012.100. View

20.

Dispenzieri A, Lacy M, Kyle R, Therneau T, Larson D, Rajkumar S . Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001; 19(14):3350-6. DOI: 10.1200/JCO.2001.19.14.3350. View